RayKnowChina Research Map
Shortlist0

ShanghaiShanghai Jiao Tong University School of Medicine

Renji Hospital

上海交通大学医学院附属仁济医院

Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Renji Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌2 papers led2 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌104 papers led5 open trials led
  4. Stomach cancer胃癌65 papers led5 open trials led
  5. Hepatoblastoma肝母细胞瘤3 papers led
  6. Retinoblastoma视网膜母细胞瘤1 paper led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤3 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤10 papers led
  10. Neuroblastoma神经母细胞瘤2 papers led
  11. Multiple myeloma多发性骨髓瘤24 papers led2 open trials led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症3 papers led
  13. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病11 papers led1 open trial led
  15. IgG4-related diseaseIgG4相关性疾病2 papers led
  16. Myasthenia gravis重症肌无力3 papers led1 open trial led
  17. Biliary atresia胆道闭锁3 papers led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  19. Takayasu arteritis大动脉炎0 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  22. Fabry disease法布雷病1 paper led
  23. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  24. Behçet disease白塞病2 papers led
  25. IgA nephropathyIgA 肾病6 papers led
  26. Primary biliary cholangitis原发性胆汁性胆管炎17 papers led1 open trial led
  27. Primary sclerosing cholangitis原发性硬化性胆管炎5 papers led
  28. Hereditary angioedema遗传性血管性水肿2 papers led

Not listed for: Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Trop2-targeted immunoPET Imaging of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Registry
    NCT06851663

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  2. Recruiting
    CD70-targeted immunoPET Imaging of Malignant Cancers
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06852638

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIEBV & screening
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 0020232024: 2220242025: 002025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
    Phase
    N/A
    Started
    2026-09
    Registry
    NCT07769866

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  2. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyImmunotherapy
Departments in papersRadiation oncology
Papers it led8
  1. Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.2024Journal for immunotherapy of cancerFree full text
  3. FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.2024Wiener klinische Wochenschrift
  4. Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases.2022Analytical chemistry
  5. The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy.2022Frontiers in immunologyFree full text
  6. Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.2022Frontiers in immunologyFree full text
  7. Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis.2022International journal of biological sciencesFree full text
  8. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2021Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status6
  1. Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCCNot yet recruitingNCT07769866Lead sponsorN/AStart 2026-09
  2. NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCCActive, not recruitingNCT06762158Lead sponsorN/AStart 2024-10
  3. Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal CancerStatus unknownNCT04437212Lead sponsorPhase 2Start 2020-07
  4. Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCCStatus unknownNCT04759235Lead sponsorStart 2020-01
  5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Study sitePhase 1Start 2024-07
  6. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
More papers found outside PubMed (not counted)6
  1. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncologyconference-abstract
  2. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncologyconference-abstract
  3. 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs)2022Immuno-Oncology Technologyarticle
  4. APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study.2022Journal of Clinical Oncologyconference-abstract
  5. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  6. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 104 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
104
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 262620212022: 121220222023: 252520232024: 232320242025: 17172025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    FGF19 Overexpression Combination Unified Study in HCC-19
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06978933

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  2. Recruiting
    DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
    Phase
    Phase 4
    Started
    2024-10
    Registry
    NCT06353126

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  3. Recruiting
    Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06519578

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  4. Recruiting
    GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT05926726

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  5. Not yet recruiting
    HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07045558

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  6. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsRecurrence & prognosisImaging, AI & early detection
Departments in papersMedical oncologyRadiology / nuclear medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led104
  1. Oridonin induces ferroptosis by inhibiting ubiquitin-mediated degradation of HMOX1 in hepatocellular carcinoma.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  2. A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.2025Acta biomaterialia
  3. Cardiorespiratory fitness-associated gene signature for prognosis in hepatocellular Carcinoma: Computational prediction and in vivo validation.2025Biochemical and biophysical research communications
  4. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.2025Cancer cell
  5. Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation.2025Cancer communications (London, England)Free full text
  6. Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.2025Cellular and molecular gastroenterology and hepatologyFree full text
  7. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  8. PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  9. Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.2025Clinical and experimental medicineFree full text
  10. Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.2025Clinical and molecular hepatologyFree full text
  11. DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.2025Developmental cell
  12. PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18.2025Hepatology communicationsFree full text
  13. Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.2025ImmunotherapyFree full text
  14. Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.2025ImmunotherapyFree full text
  15. SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism.2025International journal of biological sciencesFree full text
  16. Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.2025Journal of gastroenterologyFree full text
  17. The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.2025Oncogene
  18. Hepatocellular carcinoma: signaling pathways and therapeutic advances.2025Signal transduction and targeted therapyFree full text
  19. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.2024Acta pharmacologica SinicaFree full text
  20. Upregulation of EFCAB7 after radiofrequency ablation promoting hepatocellular carcinoma metastasis and survival by regulating PARK7.2024AgingFree full text
  21. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.2024Cancer cell
  22. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.2024Cancer letters
  23. SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1.2024Cell reports
  24. Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  25. TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  26. Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.2024Communications biologyFree full text
  27. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  28. UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.2024Hepatology (Baltimore, Md.)
  29. Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.2024Hepatology (Baltimore, Md.)
  30. NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression.2024International journal of biological sciencesFree full text
  31. Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.2024International journal of medical sciencesFree full text
  32. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.2024Journal for immunotherapy of cancerFree full text
  33. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.2024Journal of experimental & clinical cancer research : CRFree full text
  34. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?2024Journal of hepatology
  35. UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis.2024Journal of translational medicineFree full text
  36. Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma.2024Nature communicationsFree full text
  37. Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.2024Physiological reportsFree full text
  38. Identification and validation of a prognostic model based on four genes related to satellite nodules in hepatocellular carcinoma.2024Scientific reportsFree full text
  39. Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.2024Signal transduction and targeted therapyFree full text
  40. Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism.2024The journal of gene medicine
  41. GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.2024Translational research : the journal of laboratory and clinical medicine
  42. A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.2023Advanced materials (Deerfield Beach, Fla.)
  43. Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma.2023Asian journal of surgery
  44. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markersFree full text
  45. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.2023Cancer communications (London, England)Free full text
  46. Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.2023Cellular & molecular immunologyFree full text
  47. Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  48. The negative effect of G1958A polymorphism on MTHFD1 protein stability and HCC growth.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  49. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.2023Clinical and translational medicineFree full text
  50. PET imaging of tumor vascular normalization in hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  51. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  52. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.2023Frontiers in immunologyFree full text
  53. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  54. Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.2023Gastroenterology
  55. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.2023Hepatology (Baltimore, Md.)
  56. Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention.2023Hepatology communicationsFree full text
  57. Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis.2023International journal of biological sciencesFree full text
  58. Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.2023International journal of biological sciencesFree full text
  59. A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  60. RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma.2023Journal of experimental & clinical cancer research : CRFree full text
  61. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.2023Journal of translational medicineFree full text
  62. CCBE1 promotes mitochondrial fusion by inhibiting the TGFβ-DRP1 axis to prevent the progression of hepatocellular carcinoma.2023Matrix biology : journal of the International Society for Matrix Biology
  63. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.2023Molecular carcinogenesis
  64. Evolving therapeutic landscape of advanced hepatocellular carcinoma.2023Nature reviews. Gastroenterology & hepatology
  65. STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice.2023Science signalingFree full text
  66. Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma.2023Signal transduction and targeted therapyFree full text
  67. Aggregation-Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-Guided siRNA Therapy of Hepatocellular Carcinoma.2022Advanced healthcare materials
  68. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.2022BMC cancerFree full text
  69. Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin.2022BiomoleculesFree full text
  70. Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.2022Cancer letters
  71. ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma.2022Cancer letters
  72. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.2022European journal of nuclear medicine and molecular imaging
  73. Crucial role of T cells in NAFLD-related disease: A review and prospect.2022Frontiers in endocrinologyFree full text
  74. Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.2022Frontiers in immunologyFree full text
  75. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.2022Genome medicineFree full text
  76. A pre‑clinical model combining cryopreservation technique with precision‑cut slice culture method to assess the in vitro drug response of hepatocellular carcinoma.2022International journal of molecular medicineFree full text
  77. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.2022Journal of immunology researchFree full text
  78. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1.2022Oncogene
  79. CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma.2021Advanced healthcare materials
  80. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen.2021Briefings in bioinformatics
  81. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.2021Briefings in bioinformatics
  82. Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma.2021Cancer letters
  83. XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma.2021Cancer letters
  84. NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis.2021Cancer researchFree full text
  85. A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.2021Cancer research
  86. MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  87. Inhibition of AMPK activity by TRIM11 facilitates cell survival of hepatocellular carcinoma under metabolic stress.2021Clinical and translational medicineFree full text
  88. A cascade-network framework for integrated registration of liver DCE-MR images.2021Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  89. Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma.2021Current oncology (Toronto, Ont.)Free full text
  90. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.2021European journal of gastroenterology & hepatology
  91. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis.2021European journal of pharmacology
  92. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.2021Frontiers in immunologyFree full text
  93. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.2021Genome medicineFree full text
  94. Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  95. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.2021International journal of medical sciencesFree full text
  96. Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study.2021Journal of cancer research and therapeutics
  97. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment.2021Journal of digestive diseases
  98. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CRFree full text
  99. Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.2021Journal of gastroenterology and hepatology
  100. Identification of the Different Gene Expression Characteristics from Liver Cirrhosis to Hepatocellular Carcinoma Using Single-Cell Sequencing Analyses.2021Journal of immunology researchFree full text
  101. An antibody-free liver cancer screening approach based on nanoplasmonics biosensing chips via spectrum-based deep learning.2021NanoImpact
  102. EGFR activation limits the response of liver cancer to lenvatinib.2021Nature
  103. Exploring liver cancer biology through functional genetic screens.2021Nature reviews. Gastroenterology & hepatology
  104. Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma.2021OncogeneFree full text
Chinese-language papers (not in the count)1
  1. [Strategies for immunotherapy-related hepatotoxicity in liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status30
  1. FGF19 Overexpression Combination Unified Study in HCC-19RecruitingNCT06978933Lead sponsorPhase 2Start 2025-04
  2. HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCCNot yet recruitingNCT07045558Lead sponsorStart 2025-08
  3. DEB-TACE Prior to Liver Transplantation in the Treatment of HCCRecruitingNCT06353126Lead sponsorPhase 4Start 2024-10
  4. Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular CarcinomaRecruitingNCT06519578Lead sponsorN/AStart 2024-08
  5. GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular CarcinomaRecruitingNCT05926726Lead sponsorN/AStart 2023-01
  6. Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCActive, not recruitingNCT06519721Lead sponsorN/AStart 2024-08
  7. Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Lead sponsorN/AStart 2023-08
  8. IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver TransplantationStatus unknownNCT05339581Lead sponsorN/AStart 2022-05
  9. Effects of Anesthetic Methods on Hepatic Cancer Cell Function in VitroCompletedNCT04510935Lead sponsorN/AStart 2020-08
  10. Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )Status unknownNCT04443322Lead sponsorN/AStart 2020-09
  11. Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Lead sponsorN/AStart 2020-08
  12. Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Lead sponsorN/AStart 2020-12
  13. Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC RecurrenceStatus unknownNCT04506398Lead sponsorStart 2020-09
  14. Effects of Anesthetic Methods on Hepatic Cancer Cell MalignancyCompletedNCT03594188Lead sponsorN/AStart 2018-07
  15. CAR-GPC3 T Cells in Patients With Refractory Hepatocellular CarcinomaCompletedNCT03146234Lead sponsorN/AStart 2017-03
  16. Clinical and Basic Study for Pediatric Liver TransplantationStatus unknownNCT02503384Lead sponsorStart 2015-07
  17. Anti-GPC3 CAR T for Treating Patients With Advanced HCCCompletedNCT02395250Lead sponsorPhase 1Start 2015-03
  18. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  19. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  20. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  21. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  22. IMC001 for Clinical Research on Advanced Digestive System MalignanciesStatus unknownNCT05028933Study sitePhase 1Start 2021-09
  23. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  24. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  25. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  26. Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Study sitePhase 1Start 2019-08
  27. NeuWave Microwave Ablation HCC China StudyCompletedNCT03783871Study siteN/AStart 2019-02
  28. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  29. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  30. A Study of GPC3 Redirected Autologous T Cells for Advanced HCCStatus unknownNCT02715362Study sitePhase 1/Phase 2Start 2016-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 65 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.7%.

Papers led
65
2021–2025
Trials led
26
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 181820212022: 7720222023: 8820232024: 131320242025: 19192025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 12

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ImmunoPET Imaging of Pancreatic Cancer
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT06602037

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  2. Recruiting
    Target-specific immunoPET Imaging of Digestive System Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06715839

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  3. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  4. Recruiting
    Atrophic Gastritis Predicts the Risk of Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06203327

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  5. Not yet recruiting
    Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06531291

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  6. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  7. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  8. Recruiting
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06968221

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  9. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  10. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  11. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  12. Not yet recruiting
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07782294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopyImaging & AI
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicineNeurosurgery
Papers it led65
  1. Bi-phase CT radiomics nomogram for the preoperative prediction of pylorus lymph node metastasis in non-pyloric gastric cancer patients.2025Abdominal radiology (New York)
  2. Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomized Controlled Trial2025American journal of surgeryRCT
  3. Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.2025BMC cancerFree full text
  4. Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial.2025BMJ openFree full text
  5. Metabolic fingerprinting enables rapid, label-free histopathology in gastric cancer diagnosis and prognostic prediction.2025Cell reports. MedicineFree full text
  6. Nuclear translocation of CDK5RAP3 regulated by NXF3 promotes the progression of gastric cancer.2025Cellular and molecular life sciences : CMLSFree full text
  7. Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  8. High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  9. CST1 promoted gastric cancer development by activating the AKT pathway.2025Clinics (Sao Paulo, Brazil)Free full text
  10. Automated interpretation of PD-L1 CPS based on multi-AI models integration strategy in gastric cancer.2025Frontiers in immunologyFree full text
  11. Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study.2025Journal of clinical pathology
  12. Clinicopathological Characteristics of Gastric Cancer in China: A 16-Year Single-Center Retrospective Clinical Study.2025Journal of digestive diseases
  13. A machine learning-enhanced gastric cancer diagnostic method based on shell-isolated nanoparticle-enhanced Raman spectroscopy.2025Nanoscale
  14. DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer.2025Oncology reportsFree full text
  15. Renji endoscopic submucosal dissection video data set for early gastric cancer.2025Scientific dataFree full text
  16. A Retrospective Study of Laparoscopic Distal Gastrectomy Guided by Carbon Nanoparticle Suspension Injection Lymphography for Gastric Cancer.2025The American surgeon
  17. Comprehensive exome profiling identifies ARHGEF12 mutation as a driver in gastric cancer with ovarian metastasis.2025TheranosticsFree full text
  18. Effectiveness of circulating tumor cells and circulating tumor DNA in peritoneal lavage fluid for predicting metachronous peritoneal metastasis of gastric cancer.2025Translational research : the journal of laboratory and clinical medicine
  19. Total laparoscopy-assisted total gastrectomy with Da Vinci robotic system conducted by robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH): a preliminary clinical study and case report.2025World journal of surgical oncologyFree full text
  20. Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.2024BMC cancerFree full text
  21. Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective si2024BMJ openFree full text
  22. Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.2024Cancer gene therapy
  23. Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  24. Single-cell RNA transcriptomic analyses of tumor microenvironment of ovarian metastasis in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  25. Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test.2024ChemMedChem
  26. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.2024European journal of nuclear medicine and molecular imaging
  27. [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs.2024European journal of nuclear medicine and molecular imaging
  28. Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  29. Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.2024Journal of digestive diseasesRCT
  30. Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment.2024Journal of translational medicineFree full text
  31. Targeting cellular senescence as a therapeutic vulnerability in gastric cancer.2024Life sciences
  32. DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.2024Molecular biology reports
  33. CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.2023BMC cancerFree full text
  34. SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function.2023Cancer immunology, immunotherapy : CIIFree full text
  35. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.2023Cancer letters
  36. MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  37. The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  38. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  39. Gastric metastasis from renal cell carcinoma 13 years after nephrectomy.2023Journal of digestive diseases
  40. First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic 68Ga-FAPI-04 PET in Pancreatic and Gastric Cancer.2023Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  41. Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer.2022AgingFree full text
  42. Delivery of LINC00589 via mesoporous silica nanoparticles inhibits peritoneal metastasis in gastric cancer.2022Cancer letters
  43. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer.2022Gastroenterology
  44. Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer.2022Journal of digestive diseases
  45. Synchronous in situ follicular neoplasia with MALT lymphoma and intramucosal adenocarcinoma in the stomach: A case report.2022Journal of digestive diseases
  46. Trends of stomach cancer survival: A systematic review of survival rates from population-based cancer registration.2022Journal of digestive diseases
  47. Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.2022Nature communicationsFree full text
  48. Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH-Sensitive Nano Platform.2021Advanced healthcare materials
  49. Plasmonic Alloys Reveal a Distinct Metabolic Phenotype of Early Gastric Cancer.2021Advanced materials (Deerfield Beach, Fla.)
  50. Tea Drinking and Risk of Cancer Incidence: A Meta-Analysis of Prospective Cohort Studies and Evidence Evaluation.2021Advances in nutrition (Bethesda, Md.)Free full text
  51. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.2021BMC cancerFree full text
  52. Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings.2021BMC gastroenterologyFree full text
  53. Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of rapamycin signaling.2021Bosnian journal of basic medical sciencesFree full text
  54. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1.2021Cell death & diseaseFree full text
  55. ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression.2021Cell death & diseaseFree full text
  56. mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways.2021Cell reports
  57. The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.2021CellsFree full text
  58. Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value.2021Epigenomics
  59. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.2021Frontiers in endocrinologyFree full text
  60. Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  61. Diagnostic endoscopic submucosal dissection in the diagnosis of biopsy-missed gastric mucosa-associated lymphoid tissue lymphoma.2021Journal of digestive diseases
  62. Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer.2021Journal of immunology researchFree full text
  63. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.2021Signal transduction and targeted therapyFree full text
  64. Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital.2021Surgical endoscopyFree full text
  65. Sema3C promotes hepatic metastasis and predicts poor prognosis in gastric adenocarcinoma.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)8
  1. [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Thinking and strategy selection on the quality control of early gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Statistical analysis of disability-adjusted life years for stomach and colorectal cancers in Changning District of Shanghai].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Multiple primary malignancies combined with SWI/SNF complex-deficient gastric cancer: a case report and literature review].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  5. [Influence of postoperative complications on prognosis of gastric cancer-The manifestation of gastric surgeon's skill, responsibility and empathy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Current status and progression of minimally invasive surgery after neoadjuvant therapy for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Choice of function-preserving gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status43
  1. Target-specific immunoPET Imaging of Digestive System CarcinomaRecruitingNCT06715839Lead sponsorN/AStart 2024-12
  2. Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingNCT06531291Lead sponsorPhase 2Start 2024-08
  3. ImmunoPET Imaging of Pancreatic CancerRecruitingNCT06602037Lead sponsorN/AStart 2024-11
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Lead sponsorN/AStart 2023-12
  5. A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric CancerStatus unknownNCT05769725Lead sponsorPhase 2Start 2023-03
  6. Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric CancerStatus unknownNCT05795296Lead sponsorPhase 2Start 2022-12
  7. Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.Status unknownNCT05517408Lead sponsorN/AStart 2022-09
  8. Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity PatientsCompletedNCT05518929Lead sponsorPhase 4Start 2022-09
  9. HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese PatientsStatus unknownNCT05526339Lead sponsorN/AStart 2022-09
  10. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk PatientsStatus unknownNCT05510388Lead sponsorN/AStart 2022-09
  11. Anxiety Before Non-cardiac Surgery in AdultsStatus unknownNCT05596188Lead sponsorStart 2022-11
  12. Nasal Mask Kit in Gastrointestinal EndoscopyCompletedNCT05405530Lead sponsorN/AStart 2022-09
  13. High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in ObesityStatus unknownNCT04500392Lead sponsorN/AStart 2021-05
  14. Efficacy and Safety of Remimazolam Tosylate for Sedation in GastroscopyStatus unknownNCT04727034Lead sponsorN/AStart 2021-03
  15. Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly PatientsStatus unknownNCT05068180Lead sponsorPhase 4Start 2021-10
  16. Safety and Feasibility of Reversible Induction StrategyStatus unknownNCT04434963Lead sponsorStart 2021-02
  17. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly PatientsCompletedNCT05030870Lead sponsorN/AStart 2021-09
  18. A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric CancerStatus unknownNCT04152889Lead sponsorPhase 2Start 2020-04
  19. Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of StomachStatus unknownNCT05197933Lead sponsorN/AStart 2020-10
  20. High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by PropofolCompletedNCT03332433Lead sponsorN/AStart 2017-11
  21. Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric CancerStatus unknownNCT02936193Lead sponsorN/AStart 2017-08
  22. WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal EndoscopyStatus unknownNCT02436018Lead sponsorN/AStart 2015-03
  23. Adverse Events During Upper Gastrointestinal EndoscopyStatus unknownNCT01979549Lead sponsorStart 2013-12
  24. Atrophic Gastritis Predicts the Risk of Gastric CancerRecruitingNCT06203327Lead (inferred)Start 2023-12
  25. Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal EndoscopyStatus unknownNCT03736824Lead (inferred)Start 2018-01
  26. Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFBCompletedNCT02738294Lead (inferred)N/AStart 2013-06
  27. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  28. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer DiagnosisNot yet recruitingNCT07782294Study siteStart 2026-09
  29. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  30. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  31. Bovine Reinforcement in Stomach, Colorectal and Lung OperationRecruitingNCT06968221Study sitePhase 3Start 2025-05
  32. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingNCT07366528Study sitePhase 3Start 2025-12
  33. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  34. IMC001 for Clinical Research on Advanced Digestive System MalignanciesStatus unknownNCT05028933Study sitePhase 1Start 2021-09
  35. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  36. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  37. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  38. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  39. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  40. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  41. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  42. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  43. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology
Papers it led3
  1. Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.2024AAPS PharmSciTech
  2. Deciphering the role of lipid metabolism and acetylation in osteosarcoma: A comprehensive molecular analysis.2024Environmental toxicology
  3. Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws.2023Wiener klinische Wochenschrift
Earlier papers (2016–2020)16
  1. Long noncoding RNA SNHG8 promotes the proliferation of osteosarcoma cells by downregulating miR-542-3p.2020Journal of biological regulators and homeostatic agents
  2. Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells.2020Journal of natural medicines
  3. Organoid culture system for patient-derived lung metastatic osteosarcoma.2020Medical oncology (Northwood, London, England)
  4. MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.2019Journal of cellular and molecular medicine
  5. Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells.2018Cell cycle (Georgetown, Tex.)
  6. SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.2018Cell death & disease
  7. miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.2018International journal of immunopathology and pharmacology
  8. MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-β-mediated AKT/GSK-3β/SNAIL-1 signaling.2018Molecular medicine reports
  9. Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.2018Molecular oncology
  10. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.2018Oncogene
  11. Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging.2018Talanta
  12. Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  13. Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis.2017International journal of oncology
  14. miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway.2017Oncology reports
  15. CRL4BDCAF11 E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.2017Scientific reports
  16. MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy.2016Oncology reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 10 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.9%.

Papers led
10
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 5520242025: 222025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led10
  1. Development and validation of a machine-learning-based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospective multicenter study.2025Cancer
  2. Aptamer-based drug delivery for targeted therapy of imatinib-resistant gastrointestinal stromal tumor.2025Theranostics
  3. Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.2024Cancer imaging : the official publication of the International Cancer Imaging Society
  4. Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging).2024Current drug delivery
  5. Prediction of high Ki-67 proliferation index of gastrointestinal stromal tumors based on CT at non-contrast-enhanced and different contrast-enhanced phases.2024European radiology
  6. Clinical importance of tumor rupture in gastrointestinal stromal tumor.2024Journal of digestive diseases
  7. Adult Female Patient with Untreated Truncus Arteriosus Type I and Torsion of Small Bowel Gastrointestinal Stromal Tumor: A Rare Case Report.2024The American journal of case reports
  8. Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.2023Journal of translational medicine
  9. The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.2022Cancer letters
  10. Low Distribution of TIM-3+ Cytotoxic Tumor-Infiltrating Lymphocytes Predicts Poor Outcomes in Gastrointestinal Stromal Tumors.2021Journal of immunology research
Chinese-language papers (not in the count)7
  1. [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Rethinking several issues related to surgical treatment for advanced GIST in the era of targeted therapy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Identification and inner relation between gastrointestinal stromal tumor and intra-abdominal desmoid tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Act following etiquette and change with time: analysis and discussion on the difference between the current guidelines and clinical practice of gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)15
  1. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.2020Cancer medicine
  2. Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.2020Diagnostic pathology
  3. Recurrent Extra-gastrointestinal Stromal Tumor of the Vagina: A Case Report and Review of the Literature.2020Nigerian journal of clinical practice
  4. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor.2019Cancer medicine
  8. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.2018Oncology reports
  11. miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth.2017Materials science & engineering. C, Materials for biological applications
  12. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.2016Scientific reports
  14. [Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  15. [New challenges in the diagnosis and treatment of gastrointestinal stromal tumor: thinking and practice from evidence-based medicine to precision medicine].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status9
  1. Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib TherapyStatus unknownNCT05132738Lead sponsorN/AStart 2021-08
  2. Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of StomachStatus unknownNCT05197933Lead sponsorN/AStart 2020-10
  3. Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal TumorStatus unknownNCT02931981Lead sponsorStart 2016-10
  4. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  5. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  6. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  7. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  8. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  9. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 24 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.4%.

Papers led
24
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 2220212022: 7720222023: 7720232024: 3320242025: 552025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06594211

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  2. Enrolling by invitation
    Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07833046

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  3. Recruiting
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07493135

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  4. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  5. Recruiting
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07760454

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou

  6. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led24
  1. Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma.2025Acta pharmacologica SinicaFree full text
  2. Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.2025Frontiers in immunologyFree full text
  4. Dual roles of IRE1α inhibition in reversing mitochondrial ROS-induced CD8+ T-cell senescence and exerting direct antitumor effects in multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  5. Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor.2025Journal of translational medicineFree full text
  6. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).2024Cell communication and signaling : CCSFree full text
  7. The added diagnostic value of 18 F-FDG PET/CT radiomic analysis in multiple myeloma patients with negative visual analysis.2024Nuclear medicine communications
  8. From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy.2024Recent patents on anti-cancer drug discovery
  9. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.2023BMC medicineFree full text
  10. Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma.2023Cancer letters
  11. Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma.2023Cancer scienceFree full text
  12. Metabolic kinetic modeling of [11C]methionine based on total-body PET in multiple myeloma.2023European journal of nuclear medicine and molecular imaging
  13. Unravelling the imbalanced Th17-like cell differentiation by single-cell RNA sequencing in multiple myeloma.2023International immunopharmacology
  14. C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.2023Journal for immunotherapy of cancerFree full text
  15. Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.2023Leukemia research
  16. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.2022Acta pharmacologica SinicaFree full text
  17. Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.2022BioMed research internationalFree full text
  18. Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.2022Clinical and translational medicineFree full text
  19. Promising therapeutic approaches for relapsed/refractory multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  20. Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study.2022International journal of cancer
  21. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053.2022Molecular pharmaceutics
  22. Annotating BCMA Expression in Multiple Myelomas.2022Molecular pharmaceutics
  23. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053.2021European journal of nuclear medicine and molecular imaging
  24. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.2021Military Medical ResearchFree full text
Chinese-language papers (not in the count)3
  1. [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].2022Zhonghua nei ke za zhi
  2. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].2022Zhonghua yi xue za zhi
  3. [Detection of minimal residual disease in patients with multiple myeloma:current status, challenges and prospective].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status16
  1. Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F InjectionEnrolling by invitationNCT07833046Lead sponsorStart 2026-11
  2. Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple MyelomaNot yet recruitingNCT06594211Lead sponsorN/AStart 2024-10
  3. Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.Status unknownNCT05477797Lead sponsorN/AStart 2023-02
  4. PVd Versus Vd in NDMM Patients With RIStatus unknownNCT05432414Lead sponsorPhase 2Start 2022-12
  5. A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple MyelomaCompletedNCT05620420Lead sponsorStart 2022-11
  6. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  7. A Study of IMV102 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07493135Study siteEarly phase 1Start 2026-04
  8. A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaRecruitingNCT07760454Study sitePhase 1/Phase 2Start 2026-09
  9. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  10. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  11. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  13. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  14. Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma PatientsStatus unknownNCT03618602Study sitePhase 1Start 2018-04
  15. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  16. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 3 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantTreatment regimensDiagnosis & prognosis
Departments in papersRheumatology & immunologyGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shanghai for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 11 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.3%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 3320242025: 442025

4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06249438

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentImaging
Departments in papersNeurology
Papers it led11
  1. Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder.2025Acta neurologica Belgica
  2. Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD.2025Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  3. Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsFree full text
  4. Efficacy of human umbilical cord mesenchymal stem cell in the treatment of neuromyelitis optica spectrum disorders: an animal study.2025Stem cell research & therapyFree full text
  5. Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.2024Immunity, inflammation and diseaseFree full text
  6. Human NMO-IgG Induced Different Pathological and Immunological Changes in the CNS and Peripheral Tissues of Mice.2024Journal of integrative neuroscience
  7. Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.2024Neuroscience bulletinFree full text
  8. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.2022CNS neuroscience & therapeuticsFree full text
  9. Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.2022Frontiers in immunologyFree full text
  10. Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.2022Neuroimmunomodulation
  11. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.2021Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyRecruitingNCT06249438Lead sponsorPhase 1Start 2024-03

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPancreas & bile ducts
Departments in papersGastroenterology / hepatology
Papers it led2
  1. IgG4-related disease with duodenal bulb involvement.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  2. Interleukin-35 Promotes Th9 Cell Differentiation in IgG4-Related Disorders: Experimental Data and Review of the Literature.2021Clinical reviews in allergy & immunology
Chinese-language papers (not in the count)1
  1. [Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Multicenter Observational Study of PSC and IgG4-SC in ChinaStatus unknownNCT05463445Lead sponsorStart 2022-07
  2. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  3. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01
More papers found outside PubMed (not counted)1
  1. Case report of isolated gastric IgG4-related lesion and series of literature review2021Journal of Clinical Images and Medical Case Reportsarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06249438

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStandard immunotherapyAntibodies & diagnosisPregnancy, children, older adults
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 3 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 1.4%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Shanghai for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLiver transplantLong-term outcomes

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Takayasu Arteritis Clinical Trial in ChinaCompletedNCT02981979Study siteN/AStart 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Interstitial lung disease revisited].2021Zhonghua yi xue za zhi
Earlier papers (2016–2020)1
  1. Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways.2016Respirology (Carlton, Vic.)
All its trials on ClinicalTrials.gov, any status2
  1. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  2. A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06081621Study sitePhase 2Start 2023-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led3
  1. Brain Delivery of Protein Therapeutics by Cell Matrix-Inspired Biomimetic Nanocarrier.2024Advanced materials (Deerfield Beach, Fla.)
  2. Rate-dependent depression is impaired in amyotrophic lateral sclerosis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation.2022Protein & cell
Earlier papers (2016–2020)2
  1. Increased activation ability of monocytes from ALS patients.2020Experimental neurology
  2. The nuclear localization sequence mediates hnRNPA1 amyloid fibril formation revealed by cryoEM structure.2020Nature communications

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRheumatology & immunology
Papers it led2
  1. Esophageal Ulcer: Behçet's Disease or Tuberculosis?2024Digestive diseases and sciences
  2. Behcet's-like disease in a patient treated with Ixekizumab for chronic plaque psoriasis.2022Scandinavian journal of rheumatology
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 2220242025: 002025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07390123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang

  2. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led6
  1. Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.2024Clinica chimica acta; international journal of clinical chemistry
  2. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.2024Clinical and experimental medicine
  3. Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells.2022International journal of biological sciences
  4. A single-cell survey of the human glomerulonephritis.2021Journal of cellular and molecular medicine
  5. KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.2021Nephron
  6. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.2021Renal failureRCT
Earlier papers (2016–2020)3
  1. Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Progression in IgA Nephropathy.2019Nephron
  2. Contrast-enhanced ultrasonography for assessment of tubular atrophy/interstitial fibrosis in immunoglobulin A nephropathy: a preliminary clinical study.2018Abdominal radiology (New York)
  3. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.2017Oncotarget
All its trials on ClinicalTrials.gov, any status7
  1. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  2. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  4. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  5. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  6. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  7. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 17 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 5.7%.

Papers led
17
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 3320232024: 6620242025: 332025

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Biochemical Response and Clinical Outcomes in Patients With PBC
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07449793

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  2. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  3. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led17
  1. The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis.2025Journal of autoimmunity
  2. B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.2025Journal of hepatology
  3. Gut microbiome pattern impacts treatment response in primary biliary cholangitis.2025Med (New York, N.Y.)
  4. Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis.2024Clinical reviews in allergy & immunology
  5. Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.2024Gastroenterology
  6. Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases.2024Journal of autoimmunity
  7. Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.2024Journal of autoimmunity
  8. MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.2024Journal of gastroenterology
  9. Reply to: "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".2024Journal of hepatology
  10. Intestinal microbiota in biliary diseases.2023Current opinion in gastroenterology
  11. Implications of gut microbiota in autoimmune liver diseases.2023Minerva gastroenterology
  12. A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.2023Nature communications
  13. Morphological, Functional, and Tissue Characterization of Silent Myocardial Involvement in Patients With Primary Biliary Cholangitis.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  14. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis.2022Clinics in liver disease
  15. NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.2022Journal of hepatology
  16. Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.2022World journal of gastroenterology
  17. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.2021Gut microbes
Chinese-language papers (not in the count)3
  1. [The immune-modulation therapy of autoimmune liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Expression and clinical significance of interleukin-16 in patients with primary biliary cholangitis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Liver: a unique immune organ].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)17
  1. Epigenetics of Primary Biliary Cholangitis.2020Advances in experimental medicine and biology
  2. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.2020Clinical reviews in allergy & immunology
  3. Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.2019Hepatology (Baltimore, Md.)
  4. Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis.2019Journal of autoimmunity
  5. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?2019Journal of autoimmunity
  6. CTHRC1 expression in primary biliary cholangitis.2019Journal of digestive diseases
  7. [Clinicopathological analysis of anti-mitochondrial antibody negative primary biliary cholangitis-autoimmune hepatitis overlap syndrome].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  8. [Research advances of autoimmune liver diseases in 2018].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  9. Clinical analysis of liver transplantation in autoimmune liver diseases.2018Hepatobiliary & pancreatic diseases international : HBPD INT
  10. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7.2018Journal of autoimmunity
  11. Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.2017Alimentary pharmacology & therapeutics
  12. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.2017Alimentary pharmacology & therapeutics
  13. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.2017Autoimmunity reviews
  14. [Advances in the treatment of primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  15. [Research advances in autoimmune liver diseases in 2016].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  16. The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.2016Clinical reviews in allergy & immunology
  17. A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density.2016Scientific reports
All its trials on ClinicalTrials.gov, any status8
  1. Biochemical Response and Clinical Outcomes in Patients With PBCRecruitingNCT07449793Lead sponsorStart 2026-02
  2. The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingNCT07678645Lead sponsorPhase 2Start 2026-06
  3. Early Identification of Myocardial Impairment in PBCCompletedNCT03545672Lead sponsorStart 2017-10
  4. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  5. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  6. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic InjuryCompletedNCT06888115Study sitePhase 1Start 2025-03
  7. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  8. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 5 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 5.0%.

Papers led
5
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led5
  1. Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.2024Hepatology (Baltimore, Md.)
  2. Intestinal microbiota in biliary diseases.2023Current opinion in gastroenterology
  3. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.2023Hepatology (Baltimore, Md.)
  4. Implications of gut microbiota in autoimmune liver diseases.2023Minerva gastroenterology
  5. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.2022Gut
Chinese-language papers (not in the count)2
  1. [Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [The immune-modulation therapy of autoimmune liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)10
  1. CTHRC1 expression in primary biliary cholangitis.2019Journal of digestive diseases
  2. [Research advances of autoimmune liver diseases in 2018].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. Clinical analysis of liver transplantation in autoimmune liver diseases.2018Hepatobiliary & pancreatic diseases international : HBPD INT
  4. [Pathogenesis of immunoglobulin G4-related hepatobiliary disease].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  5. [Clinical observation of isolated immunoglobulin G4-related sclerosing cholangitis and immunoglobulin G4 sclerosing cholangitis combined autoimmune pancreatitis].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  6. [Research status and challenges in immunoglobulin G4-related hepatobiliary disease].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  7. Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.2017Alimentary pharmacology & therapeutics
  8. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.2017Autoimmunity reviews
  9. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.2017Autoimmunity reviews
  10. [Research advances in autoimmune liver diseases in 2016].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status4
  1. The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingNCT07678645Lead sponsorPhase 2Start 2026-06
  2. Multicenter Observational Study of PSC and IgG4-SC in ChinaStatus unknownNCT05463445Lead sponsorStart 2022-07
  3. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Study sitePhase 3Start 2026-05
  4. CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)Active, not recruitingNCT05896137Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 2 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 6.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

2 hospitals in Shanghai for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属仁济医院

Renji Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Ren Ji Hospital; RenJi Hospital; Shanghai Renji Hospital; Punan Branch of Renji Hospital; Chongqing University Renji Hospital; Renji Hospital of Shanghai Jiaotong University; Renji Hospital Affiliated; Punnan Branch of Renji Hospital

Suggest a correctionDownload the data